Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?
Arch Bronconeumol. 2022 Oct;58(10):727-728.
doi: 10.1016/j.arbres.2022.05.004.
Epub 2022 May 13.
[Article in
English,
Spanish]
Affiliations
- 1 Research Laboratory on Neuropeptides, Institute of Biomedicine of Seville (IBIS), Seville, Spain; Pediatric Intensive Care United, Virgen del Rocío University Hospital, Seville, Spain. Electronic address: mmunoz@cica.es.
- 2 Health Emergency Center 061, Seville, Spain.
- 3 Vall d'hebron Institut de Recerca (VHIR), Pulmonology Department, Ciberes, Barcelona, Spain.
- 4 Institute of Neurosciences of Castilla y León (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems, University of Salamanca, Salamanca, Spain; Group GIR-USAL: BMD (Bases Moleculares del Desarrollo), Salamanca, Spain.
No abstract available
MeSH terms
-
Antitussive Agents* / therapeutic use
-
Aprepitant / therapeutic use
-
Humans
-
Lung Neoplasms* / complications
-
Lung Neoplasms* / drug therapy
Substances
-
Antitussive Agents
-
Aprepitant